Alemtuzumab for ANCA Associated Refractory Vasculitis

NCT01405807 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Vasculitis
Microscopic Polyangiitis
Granulomatosis With Polyangiitis
Wegener's

Interventions

DRUG: Alemtuzumab

Sponsor

Cambridge University Hospitals NHS Foundation Trust